Objective-To study the changes in morbidity, mortality, and survival patterns in a population of patients with AIDS in the United Kingdom from 1982 to 1989.
Introduction
In its first decade the clinical profile of AIDS has been extensively reported and its main complications are now well recognised. The incidence of specific diseases varies according to locality owing to the varying prevalence of potential opportunist pathogens.
Broadly similar patterns are seen in temperate regions, however. A diminishing incidence of Kaposi's sarcoma among homosexual men in the United States'3 and the emergence of new opportunist pathogens, such as leishmania,4 have now been reported, and reduced mortality from pneumocystis pneumonia has also recently been found in the United States. 5 As experience has grown the management of some of the main opportunist diseases may have been improved by earlier diagnosis, better treatment, and increased use of prophylaxis.68 Such interventions are increasingly likely to affect the clinical profile of AIDS in terms of morbidity and mortality. Improved diagnosis and treatment of some diseases, however, may also highlight others. In particular, diseases that are more amenable to current treatments may be gradually replaced by those that are more resistant to treatment. The widespread introduction ofzidovudine in 1987, an antiretroviral drug which slows the rate of progression of the underlying disease, is prolonging survival.81'
The resulting longer duration of immunodeficiency may also influence the frequency and progression of other secondary infections or tumours.
To study the improving prognosis for patients with AIDS and to identify changing morbidity and mortality trends over time we conducted a retrospective analysis of patients managed at our centre from 1982 to 1989. This type of analysis helps to ensure that new approaches to care and treatment are adapted to the changing profile of the disease.
Methods
Patients-We studied the patients with AIDS who attended our hospital regularly (usually monthly or more often) for their clinical management between October 1982 and 31 December 1989. We excluded 14 patients with incomplete or unavailable notes, five who were lost to follow up, and 47 who lived elsewhere but sought advice for problems that arose while temporarily in our locality. This left 347 patients for study (342 men and five women); 285 were from the London metropolitan area; 48 were from elsewhere in the United Kingdom; and 14 were foreign nationals, half of them from sub-Saharan Africa. The racial composition was 330 white, 10 Afro-Caribbean, four Hispanic, and three Asian. Most (310) were homosexual men, 23 were bisexual men, and 14 were heterosexual men; seven were intravenous drug users. The average age at diagnosis was 37-5 years, which remained constant over time (table I) . Since April 1987 79% of patients with AIDS at our hospital have elected to be treated with zidovudine. The revised Centres for Disease Control (CDC) classification was used for defining AIDS. 12 Trial design is shown in figure 1.
Data collected-Information recorded included sex, sexual orientation, intravenous drug use, date of birth, date that AIDS was diagnosed, presenting illness for AIDS, date that Kaposi's sarcoma was diagnosed, and each episode of pneumocystis pneumonia. The use of zidovudine and prophylaxis for pneumocystis pneumonia was noted. (14) , lymphoma in 5% (17) , and progressive multifocal leucoencephalopathy in 2% (7 11 elected not to take it. All but one of the non-zidovudine group also elected not to take prophylaxis for pneumocystis pneumonia. The median survival time of those taking zidovudine was greater than 24 months compared with a median survival for the non-zidovudine group of seven months (log rank test X2= 13-2, p=00003).
Discussion
The clinical profile and prognosis of our patients with AIDS are changing. The incidence of Kaposi's sarcoma in our United Kingdom population has started to show a decline similar to that previously found in patients in the United States,'3 while pneumocystis pneumonia has remained the index diagnosis for AIDS in roughly half. The median survival time for our patients with AIDS has doubled since 1987, from 10 to 20 months, having remained stable in previous years. The improved survival applies to all main diagnostic groups. Mortality due to pneumocystis pneumonia has shown a striking recent fall, and an increasing proportion ofdeaths are now due to Kaposi's sarcoma and cerebral lymphoma.
The considerable reduction in mortality due to pneumocystis pneumonia largely accounts for the improved outlook among our patients. Several factors are likely to have influenced this reduction, including zidovudine treatment. A reduction in mortality due to pneumocystis pneumonia was found in a North American study before the introduction of zidovudine,'6 suggesting that other factors, such as earlier presentation or earlier diagnosis and treatment,'7 have been important. The finding that pneumocystis pneumonia mortality primarily relates to the extent of pneumonitis at presentation supports this. 18 Early studies on zidovudine suggested that it not only reduced the frequency of opportunist infections in the first six months of use but also reduced their severity.9 It is unclear to what extent the increased use of pneumocystis pneumonia prophylaxis and the introduction of corticosteroids for severe pneumocystis pneumonia have contributed to the falling mortality in our series. Prospective studies are required to elucidate fully the role of these treatments.
Although the numbers of specific opportunist infections other than P carinni are often too small for separate analysis, some trends can also be seen. As the morbidity of some conditions decreases and survival times improve then those disorders refractory to treatment become more manifest. These include cryptosporidiosis and progressive multifocal leucoencephalopathy, for which no effective antimicrobial agents are available, and Mycobacterium avium intracellulare infections and late relapses of cryptococcal meningitis, where current treatment has limited efficacy.
Changes have also been seen in both the presentation and prognosis of our patients with Kaposi's sarcoma. The improved survival we have seen with Kaposi's sarcoma may partly be due to a fall in deaths due to opportunist infections. A consequence of this longer survival, however, is that more patients are now developing extensive visceral Kaposi's sarcoma and are dying because of systemic disease: Kaposi's sarcoma was the commonest cause of death in 1989. Lymphoma, especially cerebral lymphoma, has also recently emerged as a more common cause of death among our patients. This may again be related to increased survival: the importance of the duration of immunosuppression in determining the incidence of lymphomas has already been reported in patients with renal transplants.'9 It is important to note that other malignancies may appear as a consequence of more prolonged immunosuppression.20
A contributory factor in improving survival in our patients has been the introduction of zidovudine in 1987. A placebo controlled study showed a considerable reduction in early mortality9 and subsequent studies have confirmed these findings.'0' Improvement in survival in our study occurred in the year that zidovudine was widely introduced. Possibly the use of zidovudine contributed to this, especially considering the poor median survival among our patients who elected not to use it, although they also tended not to use other treatments, such as pneumocystis pneumonia prophylaxis.
Considerable improvements in the outlook for patients with AIDS can be expected in the future but to help achieve this we need to change our priorities as the profile of the disease changes. Strategies for treating opportunist disease will need increasingly to focus on those diseases now causing highest morbidity and mortality. More effective antiretroviral drugs may be developed in the future but at present optimising the timing and dose of zidovudine remains an important goal if we are to maximise its benefits and minimise its toxicity.2'
The improved survival of patients with AIDS and the improved quality of life that has accompanied it are encouraging. The increased requirements for care and the changing patterns of disease, however, will need to be incorporated into the forward planning of resources. For example, the increased morbidity due to opportunist tumours has not only affected our hospital practice but has also placed increased demands on community and hospice services. It will be essential to continue to monitor the changing clinical profile of AIDS at local and regional levels to target future clinical and research priorities. No statutory statistical information exists to inform the debates surrounding these issues. Our study goes some way to providing such data by describing the characteristics and behaviour of a national sample of non-orthodox health care practitioners and their patients and the way in which such patients make use of the two systems of health care over time and with respect to particular problems.
Methods
We focused on a particular type of non-orthodox care-that provided by qualified, non-medical practitioners belonging to national professional associations that regulate the practice of their members. All the practitioners in the study were trained in acupuncture, chiropractic, homoeopathy, medical herbalism, naturopathy, or osteopathy. The study entailed an initial postal survey, conducted in March 1987, of 2152 practitioners identified from the registers of 11 national professional associations representing practitioners in the six disciplines.
The second stage entailed a survey of the patients of a stratified random sample of 146 active practitioners, identified from the postal survey. The practitioners were stratified before sampling according to professional association membership and the length of time each practitioner had been in practice. A sample size of 5% was chosen for the six associations with membership over 100, 10% for the four with membership under 100, and 20% for the smallest association. All patients attending each of these practitioners were sampled during a specified time period allocated to each practitioner between August 1987 and July 1988. The duration of the sample period ranged from three days to two weeks, depending on the level of activity of each practitioner; a minimum of 25 patients per practitioner was sampled. The sample sizes were selected to ensure that sufficient numbers of patients were sampled within each of the diagnostic categories, thus producing a representative range of the problems presented to these non-orthodox health care practitioners. For each patient attending in the sample
